Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.

Asian Pacific journal of cancer prevention : APJCP - 1 Jan 2020

Dirican Ebubekir

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cell Line, Tumor
Share to Class I Phosphatidylinositol 3-Kinases
Share to MCF-7 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 31983154
DOI: 10.31557/APJCP.2020.21.1.1
PMCID: PMC7294037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model.PMID 31983154Read ↗

Molecular aspects of breast cancer resistance to drugs (Review).Semantic proximity Read ↗

Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.Semantic proximity Read ↗

Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.Semantic proximity Read ↗

Targeted Sequencing of HER2-Positive Breast Cancer Mutations Revealed a Potential Association between PIK3CA and Trastuzumab Resistance.Semantic proximity Read ↗

New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistanceSemantic proximity Read ↗

Oncogenic Mutations in Tumorigenesis and Targeted Therapy in Breast CancerSemantic proximity Read ↗

ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell linesSemantic proximity Read ↗

Analysis of different HER-2 mutations in breast cancer progression and drug resistance.Semantic proximity Read ↗

Concurrent Mutations Associated With Trastuzumab-resistance Revealed by Single Cell SequencingSemantic proximity Read ↗

Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing.Semantic proximity Read ↗

EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review)Semantic proximity Read ↗

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.